Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis
- PMID: 11423911
- DOI: 10.1038/sj.cdd.4400836
Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill transformed cells. We have studied the expression and functionality of the TRAIL apoptotic pathway in Ewing's sarcoma. We demonstrate that tumors from patients with Ewing's sarcoma express receptors TRAIL-R1 and -R2. Using a panel of nine Ewing's sarcoma cell lines TRAIL could induce apoptosis in seven cell lines. Preincubation with interferon-gamma rendered the two resistant cell lines sensitive. TRAIL was the most potent inducer of apoptosis when compared to Fas ligand or TNF. TRAIL-mediated apoptosis could be inhibited by various caspase-inhibitors. No difference in the surface expression of TRAIL-receptors was observed between sensitive and resistant cell lines. Also, all cell lines had similar levels of expression of Flice-like inhibitory protein (FLIP) on immunoblot. However, the two resistant cell lines had only very low level expression of caspase 8 on RNA and protein level. In summary, we show that Ewing's sarcoma expresses receptors for TRAIL, and that cells are exquisitely sensitive to TRAIL-mediated apoptosis. These results may warrant clinical trials with TRAIL in Ewing's sarcoma once the safety of TRAIL for humans has been established.
Similar articles
-
Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.Cancer Res. 2001 Mar 15;61(6):2704-12. Cancer Res. 2001. PMID: 11289151
-
Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.J Orthop Res. 2003 Sep;21(5):949-57. doi: 10.1016/S0736-0266(03)00062-7. J Orthop Res. 2003. PMID: 12919886
-
Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.Gynecol Oncol. 2004 Jun;93(3):594-604. doi: 10.1016/j.ygyno.2004.03.029. Gynecol Oncol. 2004. PMID: 15196850
-
Regulation of TRAIL-induced apoptosis by ectopic expression of antiapoptotic factors.Vitam Horm. 2004;67:453-83. doi: 10.1016/S0083-6729(04)67023-3. Vitam Horm. 2004. PMID: 15110190 Review.
-
Modulation of TRAIL signaling complex.Vitam Horm. 2004;67:81-99. doi: 10.1016/S0083-6729(04)67006-3. Vitam Horm. 2004. PMID: 15110173 Review. No abstract available.
Cited by
-
USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.Mol Cancer Res. 2018 Dec;16(12):1834-1843. doi: 10.1158/1541-7786.MCR-18-0289. Epub 2018 Aug 21. Mol Cancer Res. 2018. PMID: 30131449 Free PMC article.
-
IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression.Cancer Res. 2009 Feb 1;69(3):1080-8. doi: 10.1158/0008-5472.CAN-08-2520. Epub 2009 Jan 20. Cancer Res. 2009. PMID: 19155307 Free PMC article.
-
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Am J Cancer Res. 2012;2(1):45-64. Epub 2011 Oct 9. Am J Cancer Res. 2012. PMID: 22206045 Free PMC article.
-
Interferon-gamma sensitizes resistant Ewing's sarcoma cells to tumor necrosis factor apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8 without altering chemosensitivity.Am J Pathol. 2007 Jun;170(6):1917-30. doi: 10.2353/ajpath.2007.060993. Am J Pathol. 2007. PMID: 17525260 Free PMC article.
-
Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors.J Clin Oncol. 2012 Nov 20;30(33):4141-7. doi: 10.1200/JCO.2012.44.1055. Epub 2012 Oct 15. J Clin Oncol. 2012. PMID: 23071222 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous